Late effects among colorectal cancer survivors ≥5 years after diagnosis—a systematic scoping review
JNCI Cancer Spectrum · 09.05.2026 · 10 (3)
DOI: 10.1093/jncics/pkag057 ↗Kurz gefasst
Scoping Review in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 12.06.2026. Verfasst von Toktam Pour und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cancer Survivors. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) survival is improving, yet long-term survivors remain at risk for cancer- and treatment-related late effects, which may emerge many years after diagnosis and treatment. We aimed to summarize evidence on late effects and their risk factors reported ≥5 years after CRC diagnosis, compared to cancer-free controls.
Methods
The literature search for this scoping review was conducted in PubMed, EMBASE, and Web of Science from inception to November 18, 2025. Primary research studies investigating late effects and providing relative risk estimates specifically ≥5 years after diagnosis were included. Risk of bias was assessed with the Newcastle-Ottawa-Scale. The study was registered with Open Science Framework, 10.17605/OSF.IO/JY6DX.
Results
We identified 9 observational studies that reported relative risk estimates for late effects. Seven studies had a low risk of bias and 2 were at moderate risk. The most frequently investigated late effect was incidence of diabetes (5 studies). The highest relative risks were reported for immunity disorders (5-10 years hazard ratio [HR] = 4.56, 99% CI = 1.36 to 15.31), depression (>5 years HR = 2.65, 95% CI =1.61 to 4.36), and nutritional deficiency (5-10 years HR = 1.69, 99% CI = 1.38 to 2.08). Comorbidities at diagnosis, age at diagnosis, and treatment were the most common risk factors associated with late effects.
Conclusions
This scoping review found that even ≥5 years after diagnosis late effects requiring treatment are considerably more common among CRC survivors than cancer-free controls. The small number of studies and the broad spectrum of identified late effects highlight the need for extensive research to characterize late effects to improve long-term survivorship care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Unit of Cancer Survivorship Outcomes & Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Medical Faculty, University of Heidelberg, Heidelberg, Germany.
- Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Toktam Pour, Hermann Brenner, Michael Hoffmeister
Förderung
- German Cancer Aid
Zitieren
APA
Pour, T., Urruchua Rodriguez, M. J., Thong, M. S. Y., Brenner, H., Arndt, V., & Hoffmeister, M. (2026). Late effects among colorectal cancer survivors ≥5 years after diagnosis—a systematic scoping review. JNCI Cancer Spectrum, 10(3). https://doi.org/10.1093/jncics/pkag057
Vancouver
Pour T, Urruchua Rodriguez MJ, Thong MSY, Brenner H, Arndt V, Hoffmeister M. Late effects among colorectal cancer survivors ≥5 years after diagnosis—a systematic scoping review. JNCI Cancer Spectrum. 2026;10(3). doi:10.1093/jncics/pkag057
BibTeX
@article{Pour2026,
author = {Pour, Toktam and Urruchua Rodriguez, Mary Jose and Thong, Melissa S Y and Brenner, Hermann and Arndt, Volker and Hoffmeister, Michael},
title = {Late effects among colorectal cancer survivors ≥5 years after diagnosis—a systematic scoping review},
journal = {JNCI Cancer Spectrum},
year = {2026},
volume = {10},
number = {3},
doi = {10.1093/jncics/pkag057}
}
EUVIMED